Thursday, October, 17, 2019 08:58:27

Contribution By Ojaswita Kutepatil


Zynerba wins U.S. patent for CBD based Fragile X Syndrome treatment

The new patent will be valid until 2038 while the firm expects to present ongoing study reports by the second half of 2019. Zynerba Pharmaceuticals, Inc., the leading developer of innovative pharmaceutically-produced transdermal cannabinoid treatments designed for treating rare and near-rare neuropsychiatric disorders, has recently …

Crescita, Tetra NHP partner to enhance dermatology product portfolio

The collaboration will effectively help optimize the delivery of Beta-C and several other active ingredients into patient’s skin and local tissues. Canada’s dermatology firm, Crescita Therapeutics Inc. and leading cannabinoid-derived drug provider, Tetra Bio-Pharma’s subsidiary, Tetra Natural Health (NHP) have recently announced an arrangement to …